Literature DB >> 1705001

Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.

X B Kong1, W P Tong, T C Chou.   

Abstract

Induction of 2'-deoxycytidine kinase (dCK) by 5-azacytidine (5-Aza-C) in a dCK-deficient HL-60 cell line resistant to 1-beta-D-arabinofuranosylcytosine (Ara-C) (HL-60/Ara-C) was examined by measurement of the incorporation of [3H]deoxycytidine ([3H] dCyd) into cellular DNA, the kinetic properties of purified dCK, the cytotoxic potency (IC50 values), and the DNA methylation patterns of 5-Aza-C-treated and untreated cells. Following a 72-hr exposure to 1 microM 5-Aza-C, the incorporation of [3H]dCyd into DNA was increased 6-fold and the total dCK activity was increased 12-fold, with a peak for both on day 6. The onset of dCK induction was dependent on the length of exposure time. The IC50 values for cell growth inhibition by Ara-C on day 3 were 0.08 microM for HL-60 cells, 12.5 microM for HL-60/Ara-C cells, and 0.55 microM for HL-60/Ara-C cells pretreated with 5-Aza-C for 40 hr. The Km and Vmax of dCyd for HL-60 dCK were similar to those for 5-Aza-C-induced HL-60/Ara-C dCK. The restriction enzymes Hpall, which cleaves CCGG sequences but cannot cleave at sites methylated at the internal cytosines (5'-CMeCGG), and Mspl, which cleaves sequences with internal methylated cytosine but cannot cleave at sites methylated at external cytosines (5'-MeCCGG), were used for DNA methylation pattern determination. The newly synthesized DNA of HL-60 wild-type cells was cleaved by Mspl to a greater extent than that of HL-60/Ara-C cells. After exposure to 1 microM 5-Aza-C for 40 hr, methylation patterns of newly synthesized DNA reverted in HL-60/Ara-C cells to a clevage pattern similar to that in HL-60 wild-type cells. When compared with untreated control, DNAs from 5-Aza-C-treated resistant cells were cleaved to a greater extent by Mspl than by Hpall, suggesting that internal cytosine-residue methylation was relatively uninhibited.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705001

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.

Authors:  Valeria Sebastiani; Francesca Ricci; Belen Rubio-Viqueira; Belen Rubio-Viquiera; Piotr Kulesza; Charles J Yeo; Manuel Hidalgo; Alison Klein; Daniel Laheru; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Histamine-induced differentiation of eosinophilic subclone of HL-60 cells.

Authors:  K Tasaka; T Tsurukai; K Shimada; T Abe; M Mio
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

3.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

4.  Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Authors:  C Müller-Tidow; P Tschanter; C Röllig; C Thiede; A Koschmieder; M Stelljes; S Koschmieder; M Dugas; J Gerss; T Butterfaß-Bahloul; R Wagner; M Eveslage; U Thiem; S W Krause; U Kaiser; V Kunzmann; B Steffen; R Noppeney; W Herr; C D Baldus; N Schmitz; K Götze; A Reichle; M Kaufmann; A Neubauer; K Schäfer-Eckart; M Hänel; R Peceny; N Frickhofen; M Kiehl; A Giagounidis; M Görner; R Repp; H Link; A Kiani; R Naumann; T H Brümmendorf; H Serve; G Ehninger; W E Berdel; U Krug
Journal:  Leukemia       Date:  2015-11-02       Impact factor: 11.528

5.  DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.

Authors:  Myrna Candelaria; Erick de la Cruz-Hernandez; Lucia Taja-Chayeb; Enrique Perez-Cardenas; Catalina Trejo-Becerril; Aurora Gonzalez-Fierro; Alma Chavez-Blanco; Ernesto Soto-Reyes; Guadalupe Dominguez; Jaenai E Trujillo; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 6.  Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.

Authors:  Armin Zebisch; Stefan Hatzl; Martin Pichler; Albert Wölfler; Heinz Sill
Journal:  Int J Mol Sci       Date:  2016-12-10       Impact factor: 5.923

7.  Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.

Authors:  Utz Krug; Anja Koschmieder; Daniela Schwammbach; Joachim Gerss; Nicola Tidow; Björn Steffen; Gesine Bug; Christian H Brandts; Markus Schaich; Christoph Röllig; Christian Thiede; Richard Noppeney; Matthias Stelljes; Thomas Büchner; Steffen Koschmieder; Ulrich Dührsen; Hubert Serve; Gerhard Ehninger; Wolfgang E Berdel; Carsten Müller-Tidow
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

8.  Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.

Authors:  Sucheta Jagan; Laura A Paganessi; Robin R Frank; Parameswaran Venugopal; Melissa Larson; Kent W Christopherson
Journal:  Adv Hematol       Date:  2012-09-23

9.  The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation.

Authors:  Amber Blaauboer; Peter M van Koetsveld; Dana A M Mustafa; Jasper Dumas; Fadime Dogan; Suzanne van Zwienen; Casper H J van Eijck; Leo J Hofland
Journal:  Biomedicines       Date:  2022-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.